David Loader
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- SARS-CoV-2 and COVID-19 Research 7
- COVID-19 Clinical Research Studies 4
-
- Risk Management in Financial Firms 2
- Journals
- The Lancet (5 papers)Nature (4 papers)The Lancet Diabetes & Endocrinology (3 papers)Human Genetics (1 paper)EClinicalMedicine (1 paper)
- Partner nations
- United KingdomAustraliaItaly
In The Last Decade
David Loader
38 papers receiving 2.7k citations
David Loader's Hit Papers
Peers
Comparison fields: 5 of 147
- Infectious Diseases 1.2k
- Neurology 368
- Internal Medicine 56
- Immunology 326
- Nephrology 97
Countries citing papers authored by David Loader
This map shows the geographic impact of David Loader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Loader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Loader more than expected).
Fields of papers citing papers by David Loader
This network shows the impact of papers produced by David Loader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Loader. The network helps show where David Loader may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 228 |
| 6 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 7 | Endovascular Ultrasound Renal Denervation to Treat Hypertension Hit paper breakdown → | 2023 | 122 |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 121 |
| 9 | 2023 | 83 | |
| 10 | 2002 | 80 | |
| 11 | 2023 | 77 | |
| 12 | 2023 | 67 | |
| 13 | 2023 | 65 | |
| 14 | 2023 | 56 | |
| 15 | 2021 | 24 | |
| 16 | 2023 | 24 | |
| 17 | 2024 | 23 | |
| 18 | 2023 | 23 | |
| 19 | 2002 | 22 | |
| 20 | 2024 | 8 |
About David Loader
David Loader is a scholar working on Infectious Diseases, Accounting, Finance, Immunology and Endocrinology, Diabetes and Metabolism, having authored 44 papers that have together received 2.8k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (4 papers), interferon and immune responses (3 papers), Diabetes Treatment and Management (2 papers), Risk Management in Financial Firms (2 papers), Banking stability, regulation, efficiency (2 papers), Innovative Teaching Methods (1 paper) and Insurance and Financial Risk Management (1 paper). The work is most often cited by research in Infectious Diseases (1.2k citations), Neurology (368 citations), Internal Medicine (56 citations), Immunology (326 citations) and Nephrology (97 citations). David Loader has collaborated with scholars based in United Kingdom, Australia and Italy. Their work appears in journals such as The Lancet, Nature, The Lancet Diabetes & Endocrinology, Human Genetics and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.